This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by D'Armiento, J. Articles by Chada, K. Search for Related Content PubMed PubMed Citation Articles by D'Armiento, J. Articles by Chada, K.

Identification of the Benign Mesenchymal Tumor Gene HMGA2 in Lymphangiomyomatosis

Departments of ¹ Medicine, ² Surgery, and ³ Pathology, College of Physicians and Surgeons, Columbia University, New York, New York; ⁴ Department of Biochemistry, University of Medicine and Dentistry-Robert Wood Johnson Medical School, Piscataway, New Jersey; ⁵ Facultad de Ciencias, Universidad Nacional Autonoma de Mexico and Instituto Nacional de Enfermedades Respiratorias, Mexico DF, Mexico; and ⁶ Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati, Cincinnati, Ohio

Requests for reprints: Jeanine D'Armiento, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th Street, P&S room 9-449 New York, NY 10032. Phone: 212-305-3745; Fax: 212-305-5052; E-mail: jmd12{at}columbia.edu.

The normal expression pattern of HMGA2, an architectural transcription factor, is primarily restricted to cells of the developing mesenchyme before their overt differentiation during organogenesis. A detailed in situ hybridization analysis showed that the undifferentiated mesoderm of the embryonic lung expressed Hmga2 but it was not expressed in the newborn or adult lung. Previously, HMGA2 was shown to be misexpressed in a number of benign, differentiated mesenchymal tumors including lipomas, uterine leiomyomas, and pulmonary chondroid hamartomas. Here, we show that HMGA2 is misexpressed in pulmonary lymphangiomyomatosis (LAM), a severe disorder of unknown etiology consisting of lymphatic smooth muscle cell proliferation that results in the obstruction of airways, lymphatics, and vessels. Immunohistochemistry was done with antibodies to HMGA2 and revealed expression in lung tissue samples obtained from 21 patients with LAM. In contrast, HMGA2 was not expressed in sections of normal adult lung or other proliferative interstitial lung diseases, indicating that the expression of HMGA2 in LAM represents aberrant gene activation and is not due solely to an increase in cellular proliferation. In vivo studies in transgenic mice show that misexpression of HMGA2 in smooth muscle cells resulted in increased proliferation of these cells in the lung surrounding the epithelial cells. Therefore, similar to the other mesenchymal neoplasms, HMGA2 misexpression in the smooth muscle cell leads to abnormal proliferation and LAM tumorigenesis. These results suggest that HMGA2 plays a central role in the pathogenesis of LAM and is a potential candidate as a therapeutic target. [Cancer Res 2007;67(5):1902–9]